Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Filamon LTD
Trogenix ltd
Eli Lilly and Company
Neonc Technologies, Inc.
M.D. Anderson Cancer Center
Lantern Pharma Inc.
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Essen Biotech
Essen Biotech
Grupo Español de Investigación en Neurooncología
Genenta Science
Sapience Therapeutics
Washington University School of Medicine
Cantex Pharmaceuticals
Institute of Cancer Research, United Kingdom
Tango Therapeutics, Inc.
Inovio Pharmaceuticals
Institute of Cancer Research, United Kingdom
InSightec
InSightec
Case Comprehensive Cancer Center
AHS Cancer Control Alberta
M.D. Anderson Cancer Center
Mianyang Central Hospital